Subsequent clinical validation studies to confirm the prognostic predictive ability of MALAT1 expression, if successful may find clinical utility in guiding treatment recommendations to undergo systemic adjuvant chemotherapy in a group of BC patients who might otherwise mistakenly be perceived to be at low risk of disease recurrence. Here, MALAT1 is linked to breast cancer.